Belnacasan

Belnacasan (VX-765) is a drug developed by Vertex Pharmaceuticals which acts as a potent and selective inhibitor of the enzyme caspase 1. This enzyme is involved in inflammation and cell death, and consequently blocking its action may be useful for various medical applications, including treatment of epilepsy, arthritis, aiding recovery from heart attack and slowing the progression of Alzheimer's disease. Belnacasan is an orally active prodrug, being converted in the body to the active drug VRT-043198 (O-desethyl-belnacasan). However while belnacasan has proved well tolerated in human clinical trials, it has not shown sufficient efficacy to be approved for use for any of the applications suggested to date, though research continues into possible future uses of this or similar drugs.^{[1][2][3][4][5]}

Routes of
administrationOral

CAS Number

• 273404-37-8

PubChem CID

• 11398092

ChemSpider

• 9572992

Quick facts Clinical data, Routes ofadministration ...

Belnacasan

Clinical data
Routes of administration	Oral
Identifiers
IUPAC name (2S)-1-[(2S)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide
CAS Number	273404-37-8
PubChem CID	11398092
ChemSpider	9572992
UNII	00OLE78529
KEGG	D10416
CompTox Dashboard (EPA)	DTXSID901017651
Chemical and physical data
Formula	C24H33ClN4O6
Molar mass	509.00 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCO[C@@H]3OC(=O)C[C@@H]3NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C
InChI InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)/t16-,17-,19+,23+/m0/s1 Key:SJDDOCKBXFJEJB-MOKWFATOSA-N

Close